Everything below concerns human growth hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Until the collapse of the federal government in 1991, the organisational and administrative structure of Somalia's healthcare sector was overseen by the Ministry of Health. Regional medical officials enjoyed some authority, but healthcare was largely centralised. The socialist government of former President of Somalia Siad Barre had put an end to private medical practice in 1972. Much of the national budget was devoted to military expenditure, leaving few resources for healthcare, among other services. Somalia's public healthcare system was largely destroyed during the ensuing civil war. As with other previously nationalised sectors, informal providers have filled the vacuum and replaced the former government monopoly over healthcare, with access to facilities witnessing a significant increase. Many new healthcare centres, clinics, hospitals and pharmacies have in the process been established through home-grown Somali initiatives. The cost of medical consultations and treatment in these facilities is low, at US$5.72 per visit in health centres (with a population coverage of 95%), and US$1.89–3.97 per outpatient visit and US$7.83–13.95 per bed day in primary through tertiary hospitals. Comparing the 2005–2010 period with the half-decade just prior to the outbreak of the conflict (1985–1990), life expectancy actually increased from an average of 47 years for men and women to 48.2 years for men and 51 years for women.
== Overview == Scooter's Coffee uses a franchise model to establish new stores. Some locations are drive-through only and do not have sit-in dining areas. The buildings are standardized and measure 664 square feet (61.7 m2). Its coffee is produced by Harvest Roasting, which was founded alongside Scooter's Coffee. The menu includes hot and cold drinks, including coffee, tea, and smoothies; and food items, such as pastries, burritos, and sandwiches. It also has breakfast and kids menus. Its signature drink is the Caramelicious, an espresso drink with caramel sauce and whipped cream.
=== Further reading === Resnick D, Niwayama G (January 1983). "Entheses and enthesopathy. Anatomical, pathological, and radiological correlation". Radiology. 146 (1): 1–9. doi:10.1148/radiology.146.1.6849029. PMID 6849029.
In collaboration with the Academic Medical Center in Amsterdam, Inreda Diabetic B.V. has developed a closed loop system with insulin and glucagon. The initiator, Robin Koops, started to develop the device in 2004 and ran the first tests on himself. In October 2016 Inreda Diabetic B.V. got the ISO 13485 license, a first requirement to produce its artificial pancreas. The product itself is called Inreda AP, and soon made some highly successful trials. After clinical trials, it received the CE marking, noting that it complies with European regulation, in February 2020. In October 2020 the health insurance company Menzis and Inreda Diabetic then started a pilot with 100 patients insured by Menzis. These are all patients that face very serious trouble in regulating their blood glucose levels. They now use the Inreda AP instead of the traditional treatment. Another large scale trial with the Inreda AP was set up in July 2021, and should determine whether Dutch health insurance should cover the device for all their insured. A smaller improved version of the Inreda AP is scheduled for release in 2023.
Sources: en.wikipedia.org
An added advantage of the prussian blue is that the caesium which is stripped from the animal in the droppings is in a form which is not available to plants. Hence it prevents the caesium from being recycled. The form of prussian blue required for the treatment of animals, including humans is a special grade. Attempts to use the pigment grade used in paints have not been successful.
== History == Dated back to 1956, the first protein modified transition metal catalyst was documented. The Palladium(II) salt was absorbed onto silk fibroin fiber, reduced by hydrogen to get the first reported ArM, which can catalyze asymmetric hydrogenation. This work was not reproducible, but it is considered to be the first work in the field of artificial metalloenzymes. At that time, the major challenge that blocked further studies was underdeveloped protein production and purification technology. The first attempt to anchor an abiotic metal center onto a protein was reported by Whitesides et al. using biotin-avidin interaction, making an artificial hydrogenase. The presence of avidin can significantly increase the catalytic capacity of Rhodium(I) cofactor in aqueous phosphate buffer. Another pioneering work was conducted by Kaiser et al. where carboxypeptidase A (CPA) was repurposed into an oxidase by substituting Zn(II) center by Cu(II), for the oxidation of ascorbic acid. The real potential of ArMs was unleashed when recombinant protein production was developed, namely in 1997 Distefano and Davies reported a scaffold modification of a recombinant adipocyte lipid-binding protein (ALBP) with iodoacetamido-1,10-phenanthroline coordinating Cu(II) for the stereoselective hydrolysis of racemic esters.
While BK began its foray into locations outside of the continental United States in 1963 with a store in San Juan, Puerto Rico, it did not have an international presence until several years later. Shortly after the acquisition of the chain by Pillsbury, it opened its first Canadian restaurant in Windsor, Ontario in 1969. Other international locations followed soon after, including Australia in 1971, with a restaurant in the Perth suburb of Innaloo, and Europe in 1975, with a restaurant in Madrid. Beginning in 1982, BK and its franchisees began operating stores in several East Asian countries, including Japan, Taiwan, Singapore and South Korea. Due to high competition, all of the Japanese locations were closed in 2001; however, BK reentered the Japanese market in June 2007. BK's Central and South American operations began in Mexico in the late 1970s and by the early 1980s in Caracas, Venezuela, Santiago, Chile, and Buenos Aires, Argentina. While Burger King lags behind McDonald's in international locations by over 12,000 stores, as of 2008 it had managed to become the largest chain in several countries including Mexico and Spain.
Sources: en.wikipedia.org
In the Indo-Tibetan Buddhist tradition for example, the 8 spoked wheel represents the noble eightfold path, and the hub, rim and spokes are also said to represent the three trainings (sila, prajña and samadhi). In Buddhism, the cyclical movement of a wheel is also used to symbolize the cyclical nature of life in the world (also referred to as the "wheel of samsara", samsara-chakra or the "wheel of becoming", bhava-cakra). This wheel of suffering can be reversed or "turned" through the practice of the Buddhist path. The Buddhist terms for "suffering" (dukkha) and happiness (sukha) may also originally be related to the proper or improper fitting of wheels on a chariot's axle. The Indo-Tibetan tradition has developed elaborate depictions called Bhavacakras which depict the many realms of rebirth in Buddhist cosmology. The spokes of a wheel are also often used as symbols of the Buddhist doctrine of dependent origination. According to the Theravada scholar Buddhaghosa:
Around the 1930s plant nutritionists investigated diseases of certain plants, and thereby, observed symptoms related to existing soil conditions such as salinity or nutrient deficiency. In this context, water culture experiments were undertaken with the hope of delivering similar symptoms under controlled laboratory conditions. This approach forced by Dennis Robert Hoagland led to innovative model systems (e.g., green algae Nitella) and standardized nutrient recipes playing an increasingly important role in modern plant physiology. In 1929, William Frederick Gericke of the University of California at Berkeley began publicly promoting that the principles of solution culture be used for agricultural crop production. He first termed this cultivation method "aquiculture" created in analogy to "agriculture" but later found that the cognate term aquaculture was already applied to culture of aquatic organisms. Gericke created a sensation by growing tomato vines twenty-five feet (7.6 metres) high in his backyard in mineral nutrient solutions rather than soil. He then introduced the term Hydroponics, water culture, in 1937, proposed to him by W. A. Setchell, a phycologist with an extensive education in the classics. Hydroponics is derived from neologism υδρωπονικά (derived from Greek ύδωρ=water and πονέω=cultivate), constructed in analogy to γεωπονικά (derived from Greek γαία=earth and πονέω=cultivate), geoponica, that which concerns agriculture, replacing, γεω-, earth, with ὑδρο-, water.
In October 1962 the weekly news magazine Der Spiegel published an analysis of the West German military defence. The conclusion was that there were several weaknesses in the system. Ten days after publication, the offices of Der Spiegel in Hamburg were raided by the police and quantities of documents were seized. Chancellor Adenauer proclaimed in the Bundestag that the article was tantamount to high treason and that the authors would be prosecuted. The editor/owner of the magazine, Rudolf Augstein spent some time in jail before the public outcry over the breaking of laws on freedom of the press became too loud to be ignored. The FDP members of Adenauer's cabinet resigned from the government, demanding the resignation of Franz Josef Strauss, Defence Minister, who had decidedly overstepped his competence during the crisis. Adenauer was still wounded by his brief run for president, and this episode damaged his reputation even further. He announced that he would step down in the fall of 1963. His successor was to be Ludwig Erhard. In the early 1960s, the rate of economic growth slowed down significantly. In 1962, the growth rate was 4.7%, and the following year it was 2.0%. After a brief recovery, the growth rate slowed again into a recession, with no growth in 1967. A new coalition was formed to deal with this problem. Erhard stepped down in 1966 and was succeeded by Kurt Georg Kiesinger. He led a grand coalition between West Germany's two largest parties, the CDU/CSU and the Social Democratic Party (SPD).
== Clinical significance == Polymorphisms in ACTC1 have been linked to dilated cardiomyopathy in a small number of Japanese patients. Further studies in patients from South Africa found no association. The E101K missense mutation has been associated with hypertrophic cardiomyopathy and left ventricular noncompaction. Another mutation has in the ACTC1 gene has been associated with atrial septal defects.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.